As with any medicine, the MHRA will keep the safety and effectiveness of teplizumab under close review.
Similar Posts
Clinical trials for medicines: collection, verification, & reporting of safety events
Guidance on the collection, verification, and reporting of safety events in clinical trials of an investigational medicinal product.
MHRA seizes illegal medicines worth almost £45m in 2025 – disrupting major criminal networks
Nearly 20 million doses of potentially dangerous medicines prevented from reaching the public
MHRA approves nogapendekin alfa inbakicept to treat adult patients with non-muscle invasive bladder cancer
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 July 2025, approved nogapendekin alfa inbakicept (Anktiva) for adults with BCG-unresponsive non-muscle invasive bladder cancer, where the disease remains confined to the inner lining of the bladder and may include tumours.
Class 3 Medicines Recall: Tamoxifen 20mg Film-Coated Tablets, Wockhardt UK Ltd, EL(25)A/31
Wockhardt UK Limited is recalling a batch as a precautionary measure following the identification of a dissolution failure during stability testing.
Class 4 Medicines Defect Notification: Dulcolax Adult 5 mg Gastro-resistant Tablets, Opella Healthcare UK, EL(25)A/26
Opella Healthcare UK LTD has informed the MHRA that there is an error on the artwork for the outer carton of Dulcolax Adult 5mg GR Tablets (packsize 20 count). The dose instruction incorrectly states for use in 12 years and older. These general sale packs are intended for use only in adult patients (18 years and over).
Field Safety Notices: 27 to 31 October 2025
List of Field Safety Notices from 27 to 31 October 2025.